Peptone
AI-enabled biotechnology / drug discovery
AI and experimental-biophysics platform for small-molecule discovery against intrinsically disordere
Series A
Peptone is a preclinical therapeutics and translational-biophysics company that uses experimentally measured protein dynamics, computational physics, high-performance computing, and AI to design small-molecule drug candidates against intrinsically disordered proteins (IDPs). Its stated initial therapeutic focus is oncology, with applications also described across immunology/inflammation and CNS disease. The company positions its platform around making historically difficult-to-target, dynamic proteins tractable for drug discovery; it is not a clinical-stage care-delivery AI company.
Company Details
- Website
- peptone.io
- Headquarters
- Bellinzona, Switzerland (corporate headquarters); theoretical and business-development teams in Mansfield, United Kingdom
- Funding
- $42.5M disclosed ($2.5M seed + $40M Series A)
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring